- Current Direct Investments
- Historical Direct Investments
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
Direct Investments - Current
Please navigate through the following companies. By clicking on each of their logos, you will be directed to a description of the company and a link to their website.
BARRX MEDICAL, Inc., based in Sunnyvale California is a medical device company founded to develop solutions for Barrett's esophagus, a precancerous change to the thin layer of tissue lining the esophagus. Barrett's esophagus is known to be a result of chronic Gastroesophageal Reflux Disease (GERD). The company has developed an FDA approved system that removes the Barrett's tissue in a short, endoscopic, and outpatient procedure.
Barrx Medical is an investment in the Montagu Newhall Global Partners II and Montagu Newhall Global Partners III portfolio.
BLUEARC CORPORATION, based in San Jose, California, is a provider of unified network storage systems. The company's products support both network attached storage (NAS) and storage area network (SAN) services on a converged network storage platform. The products also use Field Programmable Gate Arrays (FPGAs) and a patented embedded file system to create a massively parallel hardware appliance. The systems are designed to enable organizations to maximize performance and reduce operating costs.
BlueArc Corporation is an investment in the Montagu Newhall Global Partners IV portfolio.
CAMERON HEALTH INC., based in San Clemente, California, is a developer of implantable cardiac defibrillators. The company provides a product that is a leadless implantable cardiac defibrillator implanted only in a patient's subcutaneous tissue. Unlike current implantable cardiac defibrillators, the company's implantable cardiac defibrillators are not surgically attached to the heart, thus simplifying the implant procedure and reducing surgical complications.
Cameron Health is an investment in the Montagu Newhall Global Partners III portfolio.
CHANNELADVISOR, Inc., based in Morrisville, NC, is a provider of auction and marketplace management software and services to a wide range of sellers. The company provides channel management technology and services that enable industry-leading companies, small businesses, and individuals to use online marketplaces to acquire customers and maximize inventory yield throughout the product lifecycle. The company's customers include IBM, Motorola, Sears, Best Buy, and Dell.
ChannelAdvisor is an investment in the Montagu Newhall Global Partners II portfolio.
Concentric Medical which was founded in 1999 is a medical device company committed to opening the pathway to stroke treatment. The company is the first to complete a pivotal trial and receive FDA clearance for a device for the removal of blood clots from patients experiencing an ischemic stroke. The Merci® (Mechanical Embolus Removal in Cerebral Ischemia) Retriever is a novel therapy that removes the clot, restores blood flow and offers hope for ischemic stroke patients with no other options.
Concentric Medical is an investment in the Montagu Newhall Global Partners II portfolio.
DBS Communications was founded in 1998 in Schaumburg, Illinois. DBS is a provider of prepaid wireless services and operator of an independent mobile virtual network. The company's EZlink product lines operate on multiple wireless and long distance carrier networks, using various GSM and CDMA handsets and offer an attractively priced wireless voice and data services. The company enables organizations with retail distribution resources to distribute EZlink single and/or multiple large-scale wireless carrier networks.
DBS Communications is an investment in the Montagu Newhall Global Partners III portfolio.
DIGITAL CHOCOLATE, based in San Mateo, California, is a developer of games and applications for mobile phones. Digital Chocolate offers many of the world's most popular games including Scarlotti's Mafia Wars 2, Mobile League WordJong, Bubble Ducky, and Johnny Crash. Digital Chocolate products are available through more than 200 operator and distribution partners, including Cingular, Orange, Sprint, T-Mobile, 3, Verizon Wireless, and Vodafone in over 60 countries worldwide.
Digital Chocolate is an investment in the Montagu Newhall Global Partners
III portfolio.
Elder Health, Inc., based in Baltimore, Maryland, provides personalized medical care for the most under-served, yet highest utilizers of healthcare services: dually eligible (Medicare and Medicaid) individuals living in the community and nursing home residents. Elder Health's focus on prevention and wellness coupled with their expert understanding of the complex medical, social, spiritual and physical needs of this population has resulted in decreased use of acute and emergency services by their patients. Their model, centered around the use of Nurse Practitioners, ensures that the most appropriate clinical services are provided in the most appropriate setting to meet the required care needs for the patient.
Elder Health is an investment in the Montagu Newhall Global Partners I portfolio and the Montagu Newhall Global Partners II portfolio.
ENTELLUS MEDICAL, INC., based in Maple Grove, Minnesota, is a developer of medical devices focused on the treatment of Chronic Rhinosinusitis (CRS), an inflammation of the mucous membranes that line the inside of the sinuses. The new solution that Entellus has developed is a novel approach that enables Otolaryngologists (ENT physicians) to effectively treat CRS patients with maxillary or maxillary plus anterior ethmoid disease safely and efficiently under local anesthesia with very little bleeding or pain. Recovery time is typically 1-2 days and patients return to normal activity the next day, versus several days for traditional Functional Endoscopic Sinus Surgery.
Entellus Medical is an investment in the Montagu Newhall Global Partners III portfolio.
ExactTarget is an On-Demand Email Solutions company based in Indianapolis, Indiana. The company provides do-it-yourself, permission-based email marketing software that enables companies of all sizes to create, deliver and track personalized graphically rich email messages without technical assistance on an ASP basis.
ExactTarget is an investment in the Montagu Newhall Global Partners II
and Montagu Newhall Global Partners III portfolios.
FORHEALTH TECHNOLOGIES is a manufacturer of pharmacy-based systems that automate the preparation of sterile, intravenous (“IV”) medications. Today, IV medications are predominantly delivered in pre-mixed bags or manually measured, mixed, and filled in syringes in the hospital pharmacy or at the patient bedside. While these methods remain viable alternatives, they can lead to inaccurate medication dosages and patient safety risks, as well as wasted medications and greater costs. These highly manual and time-intensive IV medication processes are inefficient use of time for doctors and nurses.
Forhealth Technologies is an investment in the Montagu Newhall Global Partners III portfolio.
GENVAULT CORPORATION, based in Carlsbad, California, is a provider of biosample workflow, transport, and storage solutions for genomic medicine, discovery and identification. The company's dry state platform enables the extraction, preservation, recovery, and distribution of DNA at room temperature. The company's system will also accommodate proteins and RNA.
GenVault is an investment in the Montagu Newhall Global Partners III portfolio.
GLASSHOUSE TECHNOLOGIES, INC., was founded in 2001 in Framingham, Massachusetts. The Company is a provider of independent services that help organizations solve the business problems of enterprise storage. From strategy through implementation, operations and customer support, the company partners with clients to achieve predictability and manageability in storage operations, enabling cost control, risk mitigation and increased service levels.
GlassHouse Technologies is an investment in the Montagu Newhall Global
Partners III portfolio.
Intarcia Therapeutics, Inc., based in Emeryville, California, is a specialty biotechnology company, which acquires clinical stage products where early development risks have been overcome. Intarcia also focuses on the redirected development of molecules targeted at oncology, immunology, and infectious diseases. Intarcia is currently focused on the development of one primary compound, Omega Interferon. Intarcia is developing omega interferon for the first-line treatment of previously untreated and certain forms of drug-resistant hepatitis C.
Intarcia Therapeutics is an investment in the Montagu Newhall Global Partners I portfolio and the Montagu Newhall Global Partners II portfolio.
Neutral Tandem, Inc., based in Chicago, Illinois, is the industry's premier tandem service provider, facilitating the interchange of traffic between wireless, next generation, and competitive telecommunications companies. Its goal is to develop customer-centric, leading-edge products at the core of the network using its leading technology and business operations. As the leading independent provider of transit services in the nation, Neutral Tandem prides itself on its ability to proactively monitor network capacity, provide a diverse alternative to the ILEC tandem network, and reduce its customers' overall operating costs.
Neutral Tandem is an investment in the Montagu Newhall Global Partners II portfolio.
newScale, Inc., founded in 1999, is the leading provider of service delivery management software, headquartered in Foster City, California. Customers use newScale's software to automate service ordering by employees, orchestrate service delivery, and track delivery performance across both internal and external service providers. Internal service delivery includes the IT, facilities, telecommunications, security and other workplace services that all employees rely upon to perform their jobs effectively. Service delivery management enables corporations to reduce these costs and improve service quality by running internal service delivery like a business. newScale currently offers four software management solutions. Currently, newScale customers include: Target, Marriott, FedEx, Wells Fargo, Starbucks, AIG, and AT&T Wireless.
newScale is an investment in the Montagu Newhall Global Partners I and Montagu Newhall Global Partners II portfolios.
OCERA THERAPEUTICS, INC., founded in January 2005 and headquartered in San Diego, CA., is a privately held, clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for gastrointestinal and liver diseases. Ocera’s initial product candidate, AST-120, is an oral adsorbent marketed in Japan to treat patients with chronic kidney disease. Ocera was co-founded by Dr. Eckard Weber of Domain Associates and Dr. Laurent Fischer.
Ocera Therapeutics is an investment in the Montagu Newhall Global Partners III.
OREXIGEN THERAPEUTICS, INC., (NASDAQ:OREX), based in San Diego, California, is a biopharmaceutical company focused on the development of pharmaceutical product candidates for the treatment of central nervous system (CNS), disorders, with an initial focus on obesity. The Company combines individual generic drugs that have previously received regulatory approval for other indications and, thus, have established post-marketing safety records. It screens these drugs for synergistic CNS activity and combines them into new product candidates. The Company tests combinations of individual generic drugs in its product candidates in an effort to demonstrate adequate efficacy and safety for potential regulatory approval and have not received regulatory approval of any product candidate. Its lead combination product candidates targeted for obesity are Contrave, which is in a Phase III clinical trial, and Empatic, which is in a Phase IIb clinical trial.
Orexigen Therapeutics is an investment in the Montagu Newhall Global
Partners III portfolio.
PARACOR MEDICAL, INC. was founded in 1999 to pursue the development of a family of devices intended to treat heart failure in new ways. Paracor is staffed with experienced engineers developing a device intended to be implanted, without requiring the patient to undergo the effects of open chest surgery. The “HeartNet” device is a mesh support system to attenuate the impact of congestive heart failure. The company's ventricular support mesh, created out of nitinol, is designed to conform to the shape of the heart and provide elastic reinforcement to decrease stress in the heart muscle.
Paracor Medical, Inc. is an investment in the Montagu Newhall Global Partners III portfolio.
PROOFPOINT Inc., based in Cupertino California, provides both hardware- and software-based solutions for enterprise messaging security, helping enterprises, universities and government organizations stop spam, defend against viruses and ensure that outbound messages comply with both corporate policies and external regulations.
Proofpoint is an investment in the Montagu Newhall Global Partners II portfolio.
ROUNDBOX, Inc., based in Florham Park, New Jersey and with offices in Bordeaux, France and San Francisco, California, provides software products and solutions to mobile and broadcast network operators, equipment manufacturers and content providers to capitalize on the mobile broadcast market. The Company’s two existing solutions include an Electronic Service Guide (“ESG”) and a Mobile Datacasting Solution and the Company’s two supporting products include the Roundbox Broadcast Server and the Roundbox Client Toolkit. Roundbox also has a number of symbiotic programs in development that will broaden the Company’s offerings including: On Device Advertising and RoundBox Quad Play.
Roundbox is an investment in the Montagu Newhall Global Partners III portfolio.
SABRIX, Inc., was founded in 2002 and is headquartered in San Ramon, California. The Company is a provider of enterprise tax management applications. The Company's software provides complete solutions for all financial applications that require the determination, calculation, and reporting of domestic sales and use tax or international value added tax (VAT). Its software integrates with sales and purchasing applications and unlocks the value of existing enterprise resource planning (ERP) platforms by centralizing tax determination and by providing a single compliance database for either domestic or international tax organizations.
Sabrix is an investment in the Montagu Newhall Global Partners III portfolio.
SKINMEDICA Inc., based in Carlsbad California, is a provider of specialty prescription and cosmeceutical dermatology products. The company currently markets three prescription pharmaceutical products and nineteen cosmeceutical products. SkinMedica’s pharmaceutical products include: a product clinically shown to reduce unwanted facial hair in women, a hydroquinone product to treat hyperpigmentation and melasm, and acne product. The company's line of physician-dispensed, non-prescription products, “cosmeceuticals,” are designed to enhance skin appearance, reduce signs of aging and provide other skin care benefits.
SkinMedica is an investment in the Montagu Newhall Global Partners II portfolio and the Montagu Newhall Global Partners III portfolio.
TargetRx, Inc., founded in December 1999 and headquartered in Horsham, Pennsylvania, is the leading provider of marketing information services to large pharmaceutical companies. The company uses internet-based physician surveys to build a proprietary database that is the basis for products that dramatically improve sales force productivity and marketing material effectiveness.
TargetRx currently has two main products that generate the majority of their revenues; Detail Performance Monitor and Pro Sigma. The Detail Performance Monitor is focused on improving sales and marketing execution by providing pharmaceutical companies with clear information as to which sales messages and sales tactics are effective at increasing market share of their particular drugs. Pro Sigma is aimed at improving the development of promotional materials. This includes offerings to determine the best bundle of messages to use promoting a brand or the best sales pitch to use with physicians to increase usage of a brand. These offerings provide clients with confidence and precision as to whether their promotional campaign will be effective or not and how they can improve it prior to going to market.
TargetRx is an investment in the Montagu Newhall Global Partners II portfolio.
Trine Pharmaceuticals, Inc. seeks to in-license compounds, focusing on drugs to treat digestive diseases in humans. Trine Pharmaceuticals, Inc. has complimentary core technologies and a pipeline of drug candidates in various stages of clinical trials.
The company has a strong management team with considerable experience. The business management team operates in Boston, Massachusetts.
Trine Pharmaceuticals is an investment in the Montagu Newhall Global Partners I portfolio.
Verus Pharmaceuticals, Inc. was founded in 2002 in San Diego, California. The Company is a provider of products, through acquisitions and alliances, for unmet pediatric medical needs. The Company develops products with an initial focus on the treatment of asthma, allergies, and related diseases and conditions. Verus currently has two products in its pipeline, Twinject and a nebulizer.
Verus Pharmaceuticals is an investment in the Montagu Newhall Global Partners III portfolio.
VURV TECHNOLOGY, Inc., (Previously called Recruitmax) based in Ponte Vedra Beach, Florida, is a global provider of workforce management solutions. The company provides software and services, which allow large corporations and staffing companies to attract, hire, retain, and manage their workforces more efficiently. These solutions lower costs, decrease turnover, and provide companies with improved workforce visibility. Vurv’s products are web-based, delivered through HTML and JavaScript. The company has three products: Corporate Edition, Staffing Edition and Resource Edition. The Corporate Edition is designed for corporate human resource departments, which help manage the attracting, selecting and hiring of both professional and hourly workforce. Staffing Edition gives a staffing agency the tools necessary to manage the recruiting and placement process from beginning to end, including sales prospecting, recruitment and inventory (people) management. Resource Edition helps to manage planning, deployment and development of workers. It monitors the skill base and matches talent to projects while tracking costs.
Vurv Technology is an investment in the Montagu Newhall Global Partners I portfolio.
Zonare Medical Systems, Inc., based in Mountain View, California, has developed a unique ultrasound imaging technology based on the development of a revolutionary signal processing technique called "Zone Sonography." Traditional ultrasound systems rely on "beam forming" which leads to acquisition of information through individual line by line data. By contrast, Zone Sonography acquires tissue information in a single flash. Where conventional sonography was constrained by the speed of sound, Zone Sonography is limited only by the speed of the processor. The advantage of this paradigm shift in image formation results in significant opportunities for expanded workflow without performance compromise.
Zonare is an investment in the Montagu Newhall Global Partners I portfolio.
 |
 |
 |
 |
 |
Direct Investments - Historical
Please navigate through the following funds. By clicking on each of their logos, you will be directed to a description of the fund and a link to their website.
Esprit Pharma, Inc., is niche oriented pharmaceutical company focused on specialty therapeutics to improve patient outcomes in the urology therapeutic area. Led by a strong and experienced management team, the Company focuses on exploring and identifying opportunities to selectively acquire and enhance the market potential of novel, commercially available therapeutics and late-stage development drugs addressing the needs of its market space.
A privately held Company, Esprit Pharma has investment support from the leading healthcare venture capital and private equity firms of Domain Associates, LLC, New Enterprise Associates, and Apax Partners, Inc.
Esprit Pharma is an investment in the Montagu Newhall Global Partners II portfolio and Montagu Newhall Global Partners III portfolio.
Myogen , Inc., (NASDAQ:MYOG) is a Colorado-based biopharmaceutical company focused on the development of therapeutic drugs for the treatment of heart failure and related cardiovascular complications. Myogen's drugs are expected to target distinct, large segments of the Chronic Heart Failure (CHF) patient population. Myogen's products also have potential applications in other large therapeutic markets, including hypertension and kidney failure.
Myogen currently has two selective oral endothelin receptor antagonist (ERA) product candidates in late-stage clinical development: ambrisentan, which is in Phase 3 clinical development for the treatment of patients with pulmonary arterial hypertension (PAH) and darusentan, which recently completed a Phase 2b clinical trial for the treatment of patients with resistant hypertension. Myogen, Inc. completed an IPO in November 2003. The company is currently listed on the NASDAQ exchange; NASDAQ: MYOG.
Myogen was an investment in the Montagu Newhall Global Partners I portfolio.
Pharmion Inc., (NASDAQ:PHRM), based in Boulder, Colorado, is a global pharmaceutical company dedicated to acquiring, licensing and commercializing specialty pharmaceutical products. The company's initial focus is on hematology, including hematologic cancers and other blood-related syndromes. In addition, the company is pursuing products in other areas of oncology and supportive care.
By pursuing products in complementary specialty areas, Pharmion is able to leverage the skills of highly trained employees and networks of scientific experts. Medical education and science-based marketing are central to the Pharmion strategy, with emphasis placed on close working relationships with leading research and treatment centers, key associations and patient organizations.
Pharmion completed an IPO in November 2003. The company is currently listed on the NASDAQ exchange; NASDAQ: PHRM.
Pharmion is an investment in the Montagu Newhall Global Partners I portfolio.
Proxima Therapeutics, Inc., based in Alpharetta, Georgia, is a medical device company that develops and markets site-specific cancer treatment systems for breast and brain tumors. Site-specific cancer therapy enables clinicians to deliver a higher and more targeted dose of radiation or chemotherapy. This approach reduces treatment time, minimizes exposure to healthy tissue and reduces the potential for unwanted side effects. The company has commercialized two products, each of which incorporates a patented, single-use device that positions a proprietary therapeutic radiation source directly into the cancer resection site.
In February 2005, Proxima Therapeutics, Inc. was acquired by the Cytyc Corporation (NASDAQ: CYTYC).
Proxima Therapeutics was an investment in the Montagu Newhall Global Partners I portfolio.
Xcel Pharmaceuticals Inc., was a specialty pharmaceutical company based in San Diego, California. The company was organized to market and sell propriety and/or branded prescription products. The company is focusing initially on the neurology market. This is a niche therapeutic market where a limited number of high prescribing physicians write the majority of the prescriptions. The initial products (both of which were obtained from Elan Corporation) are Diastat® diazepam rectal gel for the management of patients who require intermittent use of diazepam to control bouts of increased seizure activity and Mysoline® (primidone) anticonvulsant used in control of grand, mal psychomotor and focal epileptic seizures.
In March 2005, Xcel Pharmaceuticals, Inc. was acquired by Valeant Pharmaceuticals (NYSE:VRX).
Xcel Pharmaceuticals was an investment in the Montagu Newhall Global Partners I portfolio.